Cargando…

Impact of Age on the Treatment and Survival in Esophagogastric Cancer

BACKGROUND: The age-specific risks of mortality for patients with esophagogastric cancer and their probability of surgical treatment are not well-known. METHODS: This population-based, nationwide cohort study included all patients with esophageal or gastric (esophagogastric) cancer in Sweden between...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauppila, Joonas H., Mattsson, Fredrik, Lagergren, Jesper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085923/
https://www.ncbi.nlm.nih.gov/pubmed/36648617
http://dx.doi.org/10.1245/s10434-022-13052-4
_version_ 1785022032535093248
author Kauppila, Joonas H.
Mattsson, Fredrik
Lagergren, Jesper
author_facet Kauppila, Joonas H.
Mattsson, Fredrik
Lagergren, Jesper
author_sort Kauppila, Joonas H.
collection PubMed
description BACKGROUND: The age-specific risks of mortality for patients with esophagogastric cancer and their probability of surgical treatment are not well-known. METHODS: This population-based, nationwide cohort study included all patients with esophageal or gastric (esophagogastric) cancer in Sweden between 1990 and 2013, with follow-up evaluation throughout 2018. Age at diagnosis (exposure) was categorized into nine 5-year groups. The main outcome was 5-year all-cause mortality. The secondary outcomes were 90-day all-cause mortality, 5-year disease-specific mortality, 5-year disease-specific mortality excluding 90-day all-cause mortality, and non-operation. For mortality outcomes, Cox regression provided hazard ratios (HRs) with 95% confidence intervals (95% CIs) adjusted for confounders. For non-operation, logistic regression provided odds ratios (ORs) with 95% CIs. RESULTS: Among 28,725 patients, 11,207 (39.0%) underwent surgery. For those who underwent surgery, the HRs of 5-year all-cause mortality were stable before the ages of 65 to 69 years. After that, it gradually increased for patients 65 to 69 years old (HR, 1.13; 95% CI, 1.01–1.26), patients 75 to 79 years old (HR, 1.29; 95% CI, 1.56–1.44), and patients older than 85 years (HR, 1.84; 95% CI, 1.60–2.11) compared with those younger than 50 years. Analyses of age as a continuous variable, other mortality outcomes and stratification by comorbidity and tumor type showed similar results. The odds of non-operation increased for patients 75 to 79 years old (OR, 2.09 [95% CI, 1.84–2.94] for patients 80 to 84 years old and OR, 5.00 [95% CI, 4.31–5.78] for patients ≥85 years old or older), compared with those younger than 50 years. CONCLUSION: Older age, starting from 65 years, is associated with worse survival after surgery for esophagogastric cancer, and from 75 years with lower odds of surgical treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-13052-4.
format Online
Article
Text
id pubmed-10085923
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-100859232023-04-12 Impact of Age on the Treatment and Survival in Esophagogastric Cancer Kauppila, Joonas H. Mattsson, Fredrik Lagergren, Jesper Ann Surg Oncol Thoracic Oncology BACKGROUND: The age-specific risks of mortality for patients with esophagogastric cancer and their probability of surgical treatment are not well-known. METHODS: This population-based, nationwide cohort study included all patients with esophageal or gastric (esophagogastric) cancer in Sweden between 1990 and 2013, with follow-up evaluation throughout 2018. Age at diagnosis (exposure) was categorized into nine 5-year groups. The main outcome was 5-year all-cause mortality. The secondary outcomes were 90-day all-cause mortality, 5-year disease-specific mortality, 5-year disease-specific mortality excluding 90-day all-cause mortality, and non-operation. For mortality outcomes, Cox regression provided hazard ratios (HRs) with 95% confidence intervals (95% CIs) adjusted for confounders. For non-operation, logistic regression provided odds ratios (ORs) with 95% CIs. RESULTS: Among 28,725 patients, 11,207 (39.0%) underwent surgery. For those who underwent surgery, the HRs of 5-year all-cause mortality were stable before the ages of 65 to 69 years. After that, it gradually increased for patients 65 to 69 years old (HR, 1.13; 95% CI, 1.01–1.26), patients 75 to 79 years old (HR, 1.29; 95% CI, 1.56–1.44), and patients older than 85 years (HR, 1.84; 95% CI, 1.60–2.11) compared with those younger than 50 years. Analyses of age as a continuous variable, other mortality outcomes and stratification by comorbidity and tumor type showed similar results. The odds of non-operation increased for patients 75 to 79 years old (OR, 2.09 [95% CI, 1.84–2.94] for patients 80 to 84 years old and OR, 5.00 [95% CI, 4.31–5.78] for patients ≥85 years old or older), compared with those younger than 50 years. CONCLUSION: Older age, starting from 65 years, is associated with worse survival after surgery for esophagogastric cancer, and from 75 years with lower odds of surgical treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1245/s10434-022-13052-4. Springer International Publishing 2023-01-17 2023 /pmc/articles/PMC10085923/ /pubmed/36648617 http://dx.doi.org/10.1245/s10434-022-13052-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Thoracic Oncology
Kauppila, Joonas H.
Mattsson, Fredrik
Lagergren, Jesper
Impact of Age on the Treatment and Survival in Esophagogastric Cancer
title Impact of Age on the Treatment and Survival in Esophagogastric Cancer
title_full Impact of Age on the Treatment and Survival in Esophagogastric Cancer
title_fullStr Impact of Age on the Treatment and Survival in Esophagogastric Cancer
title_full_unstemmed Impact of Age on the Treatment and Survival in Esophagogastric Cancer
title_short Impact of Age on the Treatment and Survival in Esophagogastric Cancer
title_sort impact of age on the treatment and survival in esophagogastric cancer
topic Thoracic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085923/
https://www.ncbi.nlm.nih.gov/pubmed/36648617
http://dx.doi.org/10.1245/s10434-022-13052-4
work_keys_str_mv AT kauppilajoonash impactofageonthetreatmentandsurvivalinesophagogastriccancer
AT mattssonfredrik impactofageonthetreatmentandsurvivalinesophagogastriccancer
AT lagergrenjesper impactofageonthetreatmentandsurvivalinesophagogastriccancer